相似文献
1
Molecular events in neuroendocrine prostate cancer development.神经内分泌前列腺癌发生发展中的分子事件。
Nat Rev Urol. 2021 Oct;18(10):581-596. doi: 10.1038/s41585-021-00490-0. Epub 2021 Jul 21.
2
SRRM4 Drives Neuroendocrine Transdifferentiation of Prostate Adenocarcinoma Under Androgen Receptor Pathway Inhibition.SRRM4 驱动前列腺腺癌在雄激素受体通路抑制下的神经内分泌转化。
Eur Urol. 2017 Jan;71(1):68-78. doi: 10.1016/j.eururo.2016.04.028. Epub 2016 May 11.
3
Molecular model for neuroendocrine prostate cancer progression.神经内分泌前列腺癌进展的分子模型。
BJU Int. 2018 Oct;122(4):560-570. doi: 10.1111/bju.14207. Epub 2018 Apr 24.
4
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.神经内分泌前列腺癌的分子特征分析与新药靶标的鉴定。
Cancer Discov. 2011 Nov;1(6):487-95. doi: 10.1158/2159-8290.CD-11-0130.
5
Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.鉴定治疗相关性神经内分泌前列腺癌的新型诊断生物标志物。
Pathol Oncol Res. 2021 Sep 27;27:1609968. doi: 10.3389/pore.2021.1609968. eCollection 2021.
6
Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer.神经内分泌前列腺癌的新兴治疗靶点
Curr Oncol Rep. 2025 Apr;27(4):362-374. doi: 10.1007/s11912-025-01643-9. Epub 2025 Feb 27.
7
Understanding the molecular regulators of neuroendocrine prostate cancer.了解神经内分泌前列腺癌的分子调控因子。
Adv Cancer Res. 2024;161:403-429. doi: 10.1016/bs.acr.2024.04.006. Epub 2024 May 31.
8
Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.对一名“N=1”的特殊无反应者进行全面系列分子分析，该患者为转移性前列腺癌，在治疗过程中进展为小细胞癌。
J Hematol Oncol. 2015 Oct 6;8:109. doi: 10.1186/s13045-015-0204-7.
9
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.N-Myc诱导一种由EZH2介导的转录程序驱动神经内分泌前列腺癌。
Cancer Cell. 2016 Oct 10;30(4):563-577. doi: 10.1016/j.ccell.2016.09.005.
10
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer.靶向组蛋白阅读器ZMYND8可抑制抗雄激素诱导的前列腺癌神经内分泌肿瘤转分化。
Nat Cancer. 2025 Apr;6(4):629-646. doi: 10.1038/s43018-025-00928-z. Epub 2025 Mar 18.
引用本文的文献
1
Proteomic profiling of extracellular vesicles distinguishes prostate cancer molecular subtypes.细胞外囊泡的蛋白质组学分析可区分前列腺癌分子亚型。
bioRxiv. 2025 Aug 2:2025.07.31.667906. doi: 10.1101/2025.07.31.667906.
2
RNA sequencing and immunohistochemistry jointly improve tumor biomarker interpretation.RNA测序和免疫组织化学联合应用可改善肿瘤生物标志物的解读。
Sci Rep. 2025 Aug 2;15(1):28264. doi: 10.1038/s41598-025-12780-3.
3
New Insights into Potential Therapeutic Targets for Neuroendocrine Prostate Cancer: From Bench to Clinic.神经内分泌前列腺癌潜在治疗靶点的新见解：从实验室到临床
Research (Wash D C). 2025 Jul 31;8:0791. doi: 10.34133/research.0791. eCollection 2025.
4
Reappraisal of Neuroendocrine Tumor Classification of the Prostate Gland: Translating Molecular Insights into Clinical Practice.前列腺神经内分泌肿瘤分类的重新评估：将分子见解转化为临床实践
Endocr Pathol. 2025 Jul 23;36(1):28. doi: 10.1007/s12022-025-09871-2.
5
Widespread activation and critical role of EMT and stemness in the neuroendocrine differentiation of prostate cancer (Review).上皮-间质转化（EMT）和干性在前列腺癌神经内分泌分化中的广泛激活及关键作用（综述）
Oncol Rep. 2025 Sep;54(3). doi: 10.3892/or.2025.8942. Epub 2025 Jul 11.
6
High cereblon expression in neuroendocrine cancer confers vulnerability to GSPT1 molecular glue degrader.神经内分泌癌中高表达的 Cereblon 使细胞对 GSPT1 分子胶降解剂敏感。
Exp Hematol Oncol. 2025 Jun 23;14(1):89. doi: 10.1186/s40164-025-00674-z.
7
Longitudinal single-cell analysis reveals RUNX1T1 as an early driver in treatment-induced neuroendocrine transdifferentiation.纵向单细胞分析揭示RUNX1T1是治疗诱导的神经内分泌转分化的早期驱动因素。
bioRxiv. 2025 May 18:2025.05.14.653660. doi: 10.1101/2025.05.14.653660.
8
Growth Hormone-Releasing Hormone (GHRH) Antagonist Peptides Combined with PI3K Isoform Inhibitors Enhance Cell Death in Prostate Cancer.生长激素释放激素（GHRH）拮抗剂肽与PI3K亚型抑制剂联合使用可增强前列腺癌细胞死亡。
Cancers (Basel). 2025 May 13;17(10):1643. doi: 10.3390/cancers17101643.
9
A prognostic model for highly aggressive prostate cancer using interpretable machine learning techniques.一种使用可解释机器学习技术的高侵袭性前列腺癌预后模型。
Front Med (Lausanne). 2025 May 12;12:1512870. doi: 10.3389/fmed.2025.1512870. eCollection 2025.
10
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors.BRD4抑制剂对神经内分泌前列腺癌肿瘤谱系可塑性的有效治疗靶向作用。
Acta Pharm Sin B. 2025 Mar;15(3):1415-1429. doi: 10.1016/j.apsb.2025.01.007. Epub 2025 Jan 22.
本文引用的文献
1
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.罗伐匹妥珠单抗替西瑞林治疗表达δ样蛋白3的晚期实体瘤的I/II期研究。
NPJ Precis Oncol. 2021 Aug 5;5(1):74. doi: 10.1038/s41698-021-00214-y.
2
Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms.前列腺的神经内分泌细胞：组织学、生物学功能及分子机制
Precis Clin Med. 2021 Jan 28;4(1):25-34. doi: 10.1093/pcmedi/pbab003. eCollection 2021 Mar.
3
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.与拓扑替康相比，罗伐匹妥珠单抗替西瑞林作为DLL3高表达小细胞肺癌二线治疗的疗效和安全性：3期TAHOE研究结果
J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Gene regulation by long non-coding RNAs and its biological functions.长非编码 RNA 的基因调控及其生物学功能。
Nat Rev Mol Cell Biol. 2021 Feb;22(2):96-118. doi: 10.1038/s41580-020-00315-9. Epub 2020 Dec 22.
6
Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer.单细胞分析支持人类前列腺癌中腔神经内分泌转化。
Commun Biol. 2020 Dec 16;3(1):778. doi: 10.1038/s42003-020-01476-1.
7
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.AMG 757，一种半衰期延长的、针对 DLL3 的双特异性 T 细胞衔接器，在小细胞肺癌的临床前模型中表现出高效力和高灵敏度。
Clin Cancer Res. 2021 Mar 1;27(5):1526-1537. doi: 10.1158/1078-0432.CCR-20-2845. Epub 2020 Nov 17.
8
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.SWI/SNF 复合物的特异性组成在前列腺癌谱系可塑性中的作用。
Nat Commun. 2020 Nov 3;11(1):5549. doi: 10.1038/s41467-020-19328-1.
9
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.非转移性去势抵抗性前列腺癌和达罗他胺的生存情况。
N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342.
10
A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.一种双特异性 DLL3/CD3 IgG 样 T 细胞结合抗体在小细胞肺癌中诱导抗肿瘤反应。
Clin Cancer Res. 2020 Oct 1;26(19):5258-5268. doi: 10.1158/1078-0432.CCR-20-0926. Epub 2020 Jun 18.
Zotero 插件